Marc Schwabish, the Chief Business Officer of Tectonic Therapeutic, Inc., has reported a transaction involving the withholding of shares from his stock holdings. This transaction is significant as it reflects the company's management of equity compensation in the biotechnology industry.
Background
Tectonic Therapeutic, Inc. is a biotechnology company based in Watertown, Massachusetts. The company is classified under the SIC code for Biological Products (No Diagnostic Substances) [2836]. Tectonic Therapeutic operates in a competitive sector focused on the development of innovative therapies. The company has undergone name changes in the past, previously known as AvroBio, Inc.
What the Filing Says
According to the recent SEC filing, Schwabish reported a transaction on September 25, 2026, where he disposed of 411 shares of common stock at a price of $23.67 per share. This transaction was executed to satisfy his tax withholding obligations related to the vesting of restricted stock units granted a year prior.
Impact
This transaction may affect Schwabish's personal holdings and reflects the ongoing financial management strategies employed by executives within Tectonic Therapeutic. As the company continues its operations in the biotechnology sector, such equity management practices are common among executives and may influence investor perceptions.
What's Next
The filing does not say what happens next.